Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the approval of its Cetuximab N01 Injection by the National Medical Products Administration for the treatment of metastatic colorectal cancer (mCRC) in China. The approval is based on a large-scale phase III clinical study showing the drug’s equivalence in efficacy and safety to existing treatments, potentially increasing treatment accessibility for mCRC in China where the incidence and mortality rates are rising.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry in China, focusing on developing monoclonal antibodies and other biopharmaceutical products for therapeutic use.
YTD Price Performance: 6.00%
Average Trading Volume: 292,638
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$38.57B
See more data about 6990 stock on TipRanks’ Stock Analysis page.